Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hydroxyurea Optimization Through Precision Study (HOPS): A Prospective, Multi-center, Randomized Trial of Personalized, Pharmacokinetics-guided Dosing of Hydroxyurea Versus Standard Weight-based Dosing for Children With Sickle Cell Anemia.

NCT03789591 is registered in ClinicalTrials.gov with Lifespan as lead sponsor.

NCT NCT03789591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03789591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hydroxyurea Optimization Through Precision Study (HOPS): A Prospective, Multi-center, Randomized Trial of Personalized, Pharmacokinetics-guided Dosing of Hydroxyurea Versus Standard Weight-based Dosing for Children With Sickle Cell Anemia.
Lead sponsor
Lifespan
Phase
Phase 3
Overall status
Completed
Start date
January 17, 2019
Completion date
March 19, 2025
Enrollment
104 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia, sickle cell disease